Circulating Tumor Cell Counts in Patients With Localized Prostate Cancer Including Those Under Active Surveillance

To evaluate the clinical efficacy of a circulating tumor cell (CTC) test by comparison between healthy volunteers and patients with localized prostate cancer including those under active surveillance. CTC counts in peripheral blood were compared between patients with prostate cancer (n=45) and healt...

Full description

Saved in:
Bibliographic Details
Published in:In vivo (Athens) 2019-09, Vol.33 (5), p.1615-1620
Main Authors: Choi, Se Young, Lim, Bumjin, Kyung, Yoon Soo, Kim, Yunlim, Kim, Bong Min, Jeon, Byung Hee, Park, Jae Chan, Sohn, Young Woong, Lee, Jae Hyuk, Uh, Ji-Hyun, Jang, Seongsoo, Kim, Choung-Soo
Format: Article
Language:English
Subjects:
Adult
Aged
Biomarkers, Tumor
Biopsy
Case-Control Studies
Cell Count
Humans
Male
Middle Aged
Neoplasm Grading
Neoplasm Staging
Neoplastic Cells, Circulating - pathology
Prostatic Neoplasms - diagnosis
Prostatic Neoplasms - therapy
Reproducibility of Results
Sensitivity and Specificity
Watchful Waiting
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To evaluate the clinical efficacy of a circulating tumor cell (CTC) test by comparison between healthy volunteers and patients with localized prostate cancer including those under active surveillance. CTC counts in peripheral blood were compared between patients with prostate cancer (n=45) and healthy volunteers (n=17). CTCs were identified based on the expression of epithelial cell adhesion molecule (EpCAM) and counted using a SMART BIOPSY™ SYSTEM. The number of EpCAM+ cells was significantly higher in patients with cancer than in healthy volunteers. Among the low-risk patients (n=9), two had up-staging and six had up-grading. Among those up-staged, there was one case which was EpCAM Among those cases up-graded, three were EpCAM In those with stage T2 tumors, the presence of Gleason pattern 5 was positively correlated with EpCAM positivity (rho=0.59, p
ISSN:0258-851X
1791-7549
DOI:10.21873/invivo.11645